EMA recommends approvals for both oral and high-dose pen of Wegovy - Pharmaceutical Technology

The EMA’s CHMP delivered two positive opinions, which will likely see an expansion of Novo Nordisk’s Wegovy offerings in Europe.

The guidance will now pass to the European Commission (EC) for a final decision. Credit: Uwe Aranas/Shutterstock.com.

Both an oral formulation and a high-dose injectable version of Novo Nordisk’s Wegovy (semaglutide) are edging closer to the European market, after a committee at the European Medicines Agency (EMA) backed their respective approvals.

In a meeting on 22 May, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the marketing authorisation to both versions of Wegovy. The guidance will now pass to the European Commission (EC) for a final decision, though it is expected that the pill and high-dose version will be approved. Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.